NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/02/2026
Back to search
Official data from USPTO
GLIAPHARM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
07/02/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
12/29/2016
Registration date
10/03/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/12/2024
Last transaction
07/02/2026
Responsible office
United States Patent and Trademark Office
Status code
708
Official register
Principal Register
Drawing code
3
Owner type
33
Owner location
Lausanne 26, CH
Examiner
FERRAIUOLO, DOMINIC
Current location
Historical data usage
Mark description
The mark consists of two intersecting circles with a continual line running through both circles. The lighter shaded circle stands on the right and upper side, while the darker shaded circle stands on the left and lower side. The lighter shaded circle has a line crossing through the center of the continual line. The darker shaded circle adds an additional line to create a checkmark design at the bottom of the continual line. The stylized wording "GLIAPHARM" is shown underneath the circles, with the element "GLIA" appearing in a darker shade.
Holders and representatives
Holders
Gliapharm SA
Gliapharm SA
Representatives
Flavia Campbell DICKINSON WRIGHT PLLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biological preparations for the prevention and treatment of neurological diseases; pharmaceutical preparations for the prevention and treatment of neurological diseases; chemical preparations for the prevention and treatment of neurological diseases; pharmaceutical products for the prevention and treatment of neurological diseases; medicines for the prevention and treatment of neurological diseases; diagnostic preparations for medical use; biomarking diagnostic reagents for medical use; plant extracts for pharmaceutical use
Class 42
Clinical trialsscientific laboratory servicesbiological researchscientific researchresearch and development of new products for otherschemical research
Publications
History of USPTO decisions and trademark events.
35 publications found
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
02/19/2026
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
02/03/2026
INPC
INVALIDATION PROCESSED
02/03/2026
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
08/12/2025
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
12/12/2024
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
12/12/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/18/2024
ES75
TEAS SECTION 71 & 15 RECEIVED
04/02/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/03/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/16/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/18/2018
FIMP
FINAL DISPOSITION PROCESSED
01/18/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/03/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
10/03/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/18/2017
PUBO
PUBLISHED FOR OPPOSITION
07/18/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/28/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/06/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
06/06/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/06/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
06/06/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/06/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/03/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/02/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/02/2017
RFNT
REFUSAL PROCESSED BY IB
05/27/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/11/2017
RFRR
REFUSAL PROCESSED BY MPU
05/11/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/06/2017
CNRT
NON-FINAL ACTION WRITTEN
05/05/2017
MAFR
APPLICATION FILING RECEIPT MAILED
05/02/2017
DOCK
ASSIGNED TO EXAMINER
04/28/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/27/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/20/2017
Continuous trademark protection
Get notified about every new filing that threatens GLIAPHARM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.